Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine IMA201-101)

Next Previous
Trial Profile

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine IMA201-101)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMA-201 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications Carcinoma; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms ACTengine
  • Sponsors Immatics US

Most Recent Events

  • 18 Jan 2024 Status changed from active, no longer recruiting to completed.
  • 21 Mar 2023 According to an Immatics N.V. media release, the company plans to discontinue this program after treatment of the remaining patients already enrolled in this trial in order to focus on its TCR Bispecific program TCER IMA401 addressing the identical target peptide derived from MAGEA4/8 as IMA201.
  • 03 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Apr 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top